Porphyria cutanea tarda |
Familial PCT; PCT; UROD deficiency; Uroporphyrinogen decarboxylase deficiency |
Clinical Trial: Diagnostic and Screening Study of Genetic Disorders
This study has been completed.
|
Purpose
OBJECTIVES: I. Determine the phenotypic heterogeneity of patients with genetic disorders including their clinical spectrum and natural history. II. Develop and evaluate novel methods for the treatment of genetic disorders including metabolic manipulation, enzyme manipulation, enzyme replacement, enzyme transplantation, and gene transfer techniques in these patients. III. Develop and evaluate methods for the prenatal diagnosis of genetic disorders using improved cytogenetic, biochemical, and nucleic acid techniques and amniotic fluid cells or chorionic villi in these patients.
| Condition |
|---|
| Tay-Sachs Disease Porphyria, Erythropoietic Leukodystrophy, Globoid Cell Metabolism, Inborn Errors |
MedlinePlus related topics: Genetic Disorders; Leukodystrophies; Metabolic Disorders; Porphyria; Skin Diseases; Tay-Sachs Disease
Genetics Home Reference related topics: Krabbe disease; Tay-Sachs disease; congenital erythropoietic porphyria
Study Type: Observational
Study Design: Screening
Expected Total Enrollment: 50
Study start: December 1999
PROTOCOL OUTLINE: Patients are evaluated annually or biannually, depending on disease status and progression. Patients undergo a complete medical history, an extensive family pedigree, and a physical examination. Patients undergo general laboratory, imaging, physiologic, and clinical laboratory studies according to their disease type. Patients undergo specialized laboratory studies including plasma and leukocyte enzyme assays, quantitative urinary mucopolysaccharides and oligosaccharides, urine and plasma glycolipids, plasma and urine amino acids, urine organic acids, lymphoblastoid culture, DNA isolation from peripheral leukocytes, skin biopsy for fibroblast culture (if indicated), and medical photography. Patients also receive consultations with various specialties including ophthalmology, ENT, cardiology, pulmonary, gastroenterology/nutrition, hematology, neurology, orthopedics, rehabilitation medicine/physical therapy, and dermatology.
Eligibility
Genders Eligible for Study: Both
Criteria
- Suspected diagnosis (homozygous or heterozygous) of a genetic disorder including, but not limited to, one of the following: Tay-Sachs disease (adult form) Congenital erythropoietic porphyria Galactosemia Mitochondrial myopathy Globoid cell leukodystrophy (Krabbe disease) Methylmalonic acidemia Isovaleric acidemia Morquio type A Glycogen storage disease type 1AB Ornithine aminotransferase deficiency Ceroid lipofuscinosis Glutaric aciduria type 1 Citrullinemia Other malformation syndromes, lysosomal storage disorders, or peroxisomal disorders
Location Information
New York
Mount Sinai School of Medicine, New York, New York, 10029, United States
Judith P. Willner, Study Chair, Mount Sinai Medical Center
More Information
Record last reviewed: April 2002
Last Updated: October 13, 2004
Record first received: July 5, 2000
ClinicalTrials.gov Identifier: NCT00006057
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


